Home > NEWS
DAPAGLIFLOZIN(A treatment for type 2 diabetes) suppier---SENOVA
release time:2020-09-22

API information:

Product name:Dapagliflozin propanediol monohydrate                        Cas No.:960404-48-2

Molecular Formula:C24H35ClO9      Molecular Weight:502.9823

Structure:

                             


Key intermediates information:

Product name:5-bromo-2-chloro-4'-ethoxydiphenylmethane      

Cas No.:461432-23-5

Molecular Formula:C15H14BrClO      Molecular Weight:325.62806

Structure:

                      


Product name:

(2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxyMethyl)-2-Methoxytetrahydro-2H-pyran-3,4,5-triol      

Cas No.:714269-57-5

Molecular Formula:C22H27ClO7      Molecular Weight:438.89858

Structure:

                      


Product name:D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-, tetraacetate, (1S)-      

Cas No.:461432-25-7

Molecular Formula:C29H33ClO10      Molecular Weight:577.01932

Structure:

                      



Product name:Dapagliflozin  

Cas No.:461432-26-8

Molecular Formula:C21H25ClO6      Molecular Weight:408.8726

Structure:


                      


.................................................................................................................................................................


Dapagliflozin is a sodium-glucose co-transporter 2 inhibitor. On January 8, 2014, the US Food and Drug Administration (FDA) have approved it for being used in the treatment of type II diabetes.Dapagliflozin works through inhibiting sodium-glucose transporter 2 (SGLT2), a protein in the kidney that reabsorbs glucose into the bloodstream. Meanwhile, FDA requires the producers to conduct post-marketing research on drug-related risks.

Treatment with empagliflozin and dapagliflozin reduces all-cause mortality and improves renal outcomes in patients with heart failure with reduced ejection fraction (HFrEF), suggests a recent study in the journal Lancet.


..................................................................................................................................................................


The global prevalence of diabetes among adults over 18 years of age rose from 4.7% in 1980 to 8.5% in 2014.SENOVE started to study Dapagliflozin API in 2015,The same as Empagliflozin API, it only took two years from small trial to medium trial to commercialization.The capacity of Dapagliflozin API is 500kg/month and The capacity of the key intermediates are 1000~3000kg/month now.


Headquarter Office in ShenZhen, R&D center in HangZhou, GMP factory in JiangSu.

(Please note:All products which might have patent infringment are used for R&D only/ It's Not Senova's responsibility in those markets where there are patent infringement regulated.)

OUR PLANT:



WORKSHOP
 

R&D ROOM:


 

WAREHOUSE:


PACKING: 


 COA:


.................................................................................................................................................................

SENOVA:


Senova means“Step For Innovation", we are a professional company who's supplying APIs(mainly New Generics), Advanced Intermediates and KSM(Key Starting Materials) as well as technical Support/Registration support/Custom synthesis service in pharmaceutical and related field , we focus on serving those manufacturers' New Generics Projects from R&D stage to Commercial Stage from meterials to documents support(DMF/CMC). For those regulated markets, we secure all of our products can be produced under GMP regulation with Full Documentation.





Copyright Copyright (C) 2015-2035 Senova Technology Co. Ltd.
Address: 311# in Building 3 of North Area, Dayuan Industry Park, Xili, Nanshan District of Shenzhen,China 518055  Tel: +86-0755-8670 3119 QQ: 530953397